Harrow, Inc. (HROW)
(Delayed Data from NSDQ)
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 6:42 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 6:42 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Bull Of The Day: Harrow Health (HROW)
by Brian Bolan
This "roll up" play is expected to post some good growth this year as well as next.
5 Small Hidden Gems to Pick From a Rangebound Wall Street
by Nalak Das
We have narrowed our search to five stocks that have provided more than 50% returns year to date with more upside left. These are: CRD.A, REPX, UVE, ASUR and HROW.
Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed the most recent trading day at $23.50, moving -0.63% from the previous trading session.
Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings
by Zacks Equity Research
Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings are part of the Zacks Screen of the Week article.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are TGLS, CRD.B, REPX, HROW and LNTH.
Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength
by Zacks Equity Research
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed the most recent trading day at $22.13, moving -0.23% from the previous trading session.
Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
4 Medical Stocks to Buy as Rate Hike Cycle Nears End
by Indrajit Bandyopadhyay
We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.
Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus
by Zacks Equity Research
Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength Amid March Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Community Health (CYH) to Divest Two NC Hospitals for $320M
by Zacks Equity Research
Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs
by Zacks Equity Research
Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why
by Zacks Equity Research
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Sharecare, Inc. (SHCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 80% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cano Health, Inc. (CANO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 75% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 12% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LHC Group (LHCG) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
LHC (LHCG) delivered earnings and revenue surprises of -22.63% and 6.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical's (SEM) Rising Stake in Concentra to Aid
by Zacks Equity Research
Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.
Why Seasoned Investors are Retaining Select Medical (SEM) Stock
by Zacks Equity Research
Select Medical (SEM) is focused on making strategic acquisitions to boost its business through inorganic growth.
Acadia (ACHC) & Orlando Health Form JV, Boosts Presence
by Zacks Equity Research
Acadia Healthcare Company (ACHC) expects to take on Orlando Health South Seminole Hospital's management responsibilities of the behavioral health program.
Why Seasoned Investors are Retaining Acadia (ACHC) Stock
by Zacks Equity Research
Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.